Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Time to Sell?
by Renee Jackson · The Cerbat GemSysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $9.11, but opened at $8.69. Sysmex shares last traded at $9.03, with a volume of 347 shares.
Wall Street Analysts Forecast Growth
Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.
Read Our Latest Report on SSMXY
Sysmex Trading Down 1.1%
The firm has a market capitalization of $5.67 billion, a price-to-earnings ratio of 18.77 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The business has a fifty day moving average price of $8.89 and a 200 day moving average price of $9.82.
Sysmex (OTCMKTS:SSMXY – Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $837.32 million during the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. As a group, equities analysts forecast that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.
Sysmex Company Profile
Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.